DOI: 10.1128/mBio.02368-14
Article Information
PubMed
Published By
History
- Received November 21, 2014
- Accepted February 16, 2015
- Published online March 24, 2015.
Copyright & Usage
Copyright © 2015 Gebhart et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 3.0 Unported license.
Editors and / or Reviewers
- Anne K. Vidaver, Editor, University of Nebraska
Author Information
- Dana Gebharta,
- Stephen Loka,
- Simon Clareb,
- Myreen Tomasc,d,
- Mark Starese,
- Dean Scholla,
- Curtis J. Donskeyc,d,
- Trevor D. Lawleye,
- Gregory R. Govonia
- aAvidBiotics Corp., South San Francisco, California, USA
- bMicrobial Pathogenesis Laboratory, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
- cGeriatric Research Education and Clinical Center, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA
- dDivision of Infectious Diseases & HIV Medicine, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
- eHost Microbiota Interactions Laboratory, Wellcome Trust Sanger Institute, Hinxton, United Kingdome
- Address correspondence to Gregory R. Govoni, greg{at}avidbiotics.com.
Citation Gebhart D, Lok S, Clare S, Tomas M, Stares M, Scholl D, Donskey CJ, Lawley TD, Govoni GR. 2015. A modified R-type bacteriocin specifically targeting Clostridium difficile prevents colonization of mice without affecting gut microbiota diversity. mBio 6(2):e02368-14. doi:10.1128/mBio.02368-14.
